Ophthalmia neonatorum

Summary

Ophthalmia neonatorum (MONDO:0004854) is a disease and 2 clinical trials. Top therapeutic interventions include erythromycin and rifamycin. A subtype of gonococcal conjunctivitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ophthalmia neonatorum
Mondo ID	MONDO:0004854
MeSH	D009878
DOID	DOID:9699
NCIT	C116815
SNOMED CT	34298002
UMLS	C0029076
MedGen	14489
GARD	0024121
Is cancer (heuristic)	no

Also known as: gonococcal conjunctivitis (neonatorum) · neonatal conjunctivitis

Disease family

This is a subtype of gonococcal conjunctivitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › gonorrhea › gonococcal conjunctivitis › ophthalmia neonatorum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000120	PHASE3	COMPLETED	Clinical Trial of Eye Prophylaxis in the Newborn
NCT03528915	Not specified	COMPLETED	Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ERYTHROMYCIN	4	1
RIFAMYCIN	4	1